Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Qiagen"


7 mentions found


The U.S. dollar index hit its highest level since March earlier this month, while its 50-day moving average is showing signs of surpassing its 200-day counterpart. European stocks to benefit Bank of America's screen captures European companies that would "tend to outperform" when the U.S. dollar index rises. They also had a "significant and positive slope from regression [against] the U.S. dollar index." "Over the past five years, Low Risk stocks, Energy and Norway have tended to outperform the most when the DXY index has been rising," she added. Elsewhere Dutch media house Wolters Kluwer , Italian energy player Tenaris and Finnish telecommunication services provider Nokia also appeared on the screen.
Persons: BofA's Paulina Strzelinska, Strzelinska, Wolters, — CNBC's Michael Bloom Organizations: U.S, Bank of America, The U.S, Bank, Energy, Bank of, Tobacco, Diageo, BP, Bayer, Roche, Wolters Kluwer, Nokia Locations: The, Europe, Norway, Novozymes, Denmark, Qiagen, Germany, Switzerland
March 1 (Reuters) - Qiagen (QIA.DE) is to collaborate with Sophia Genetics (SOPH.O) on its next-generation sequencing (NGS) kits, the US-German pharmaceutical company said on Wednesday. The alliance, part of Qiagen's Qiqseq platform partnership program, aims to increase the compatibility of its NGS kits with third-party digital data-sharing and analytics companies. "The partnership with Sophia Genetics is planned to be expanded to other areas of analysis," it added. Reporting by Tristan Chabba in Gdansk Editing by Miranda MurrayOur Standards: The Thomson Reuters Trust Principles.
Qiagen acquires DNA-biometrics firm Verogen in $150 mln deal
  + stars: | 2023-01-09 | by ( ) www.reuters.com   time to read: +1 min
Jan 9 (Reuters) - Life sciences firm Qiagen said on Monday it has acquired DNA-biometrics firm Verogen in a $150-million cash deal, strengthening its forensics portfolio. Qiagen expects about $20 million of sales from the Verogen portfolio this year. The deal is expected to be dilutive to Qiagen's 2023 adjusted profit per share by about 3 cents and neutral to the firm's 2024 profit. San Diego-based Verogen, founded in 2017, provides DNA-based human identification products and services, which are used in forensic analysis and to help resolve criminal and missing persons cases. Verogen's portfolio will complement Qiagen's sample collection and preparation kits, which are used to separate human DNA from forensic investigation samples for analysis.
Lyft (LYFT) – Lyft sank 17.3% in premarket action after its latest quarterly report showed slowing revenue growth and ridership levels that remain below pre-pandemic levels. The ride-hailing service did, however, report better-than-expected earnings for its latest quarter. TripAdvisor (TRIP) – TripAdvisor shares plummeted 20.8% in premarket trading after the travel website operator's quarterly earnings came in below Wall Street forecasts. Coty (COTY) – The cosmetics company reported earnings that matched Wall Street estimates, with revenue slightly above analysts' forecasts. Planet Fitness (PLNT) – The fitness center operator's stock surged 7.1% in the premarket after its quarterly revenue and profit beat Wall Street estimates and it raised its full-year forecast.
Lab tie-up would have multiple ailments
  + stars: | 2022-10-11 | by ( ) www.reuters.com   time to read: +2 min
LONDON, Oct 11 (Reuters Breakingviews) - Qiagen (QIA.DE) may once again find itself at the centre of an M&A drama. The $10 billion German lab tester is in talks with $10 billion U.S. life-science company Bio-Rad (BIO.N), the Wall Street Journal reported on Monday. Any deal would follow Thermo Fisher Scientific’s (TMO.N) failed attempt to buy Qiagen for 11.3 billion euros ($11 billion) back in 2020. Regulators in the United States and Europe have been increasingly wary of tie-ups that could lead to higher prices. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
Diagnostics firm Bio-Rad in talks to merge with Qiagen - WSJ
  + stars: | 2022-10-10 | by ( ) www.reuters.com   time to read: +1 min
Oct 10 (Reuters) - California-based diagnostics company Bio-Rad Laboratories (BIO.N) is in talks to merge with Qiagen NV (QIA.DE), the Wall Street Journal reported on Monday, citing people familiar with the matter. U.S-listed shares of Qiagen rose 8% while Bio-Rad fell nearly 10% after the report. Register now for FREE unlimited access to Reuters.com RegisterBio Rad, which manufactures and supplies products such as laboratory apparatus, instruments and diagnostics, has a market-cap of $12.85 billion. Both Qiagen and Bio-Rad did not immediately respond to Reuters' requests for comments. Register now for FREE unlimited access to Reuters.com RegisterReporting by Bhanvi Satija in Bengaluru; Editing by Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.
Qiagen has developed technologies that isolate and process DNA, RNA and proteins from blood, tissue and other materials. Bio-Rad Laboratories is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter. The talks have been going on for a while but any agreement isn’t likely for another few weeks or more—and there may not be one.
Total: 7